On February 10, 2020, in Acetris Health, LLC v. United States, No. 2018-2399, the Court of Appeals for the Federal Circuit found that the Active Pharmaceutical Ingredient (API) of a drug is not determinative of its country of origin, affirming in relevant part a U.S. Court of Federal Claims ruling. For those pharmaceutical products covered by the ruling, this holding contradicts the longstanding position of Customs and Border Protection (CBP), the agency tasked with making “substantial transformation” determinations, which has generally held that the country of origin of the API was determinative of country of origin. However, as discussed in more detail below, the court’s holding does not appear to apply to all manufacturing scenarios and thus, arguably, the holding is more limited than it may initially appear.
Sidley Austin LLP provides this information as a service to clients and other friends for educational purposes only. It should not be construed or relied on as legal advice or to create a lawyer-client relationship. Readers should not act upon this information without seeking advice from professional advisers. In addition, this information was not intended or written to be used, and cannot be used, by any person for the purpose of avoiding any U.S. federal, state or local tax penalties that may be imposed on such person.
Attorney Advertising—Sidley Austin LLP, One South Dearborn, Chicago, IL 60603. +1 312 853 7000. Sidley and Sidley Austin refer to Sidley Austin LLP and affiliated partnerships, as explained at www.sidley.com/disclaimer.
© Sidley Austin LLP